Hepatitis C treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Hepatitis C Treatment Market is Segmented By Drug Class (HCV Protease Inhibitors, HCV Polymerase Inhibitors, Combination Therapy, Interferon, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Hepatitis C Treatment Market Overview

The Hepatitis C Treatment Market is expected to reach at a CAGR of 13.5% during the forecast period (2023-2030). Infection with the hepatitis C virus (HCV) produces inflammation in the liver, leading to various issues, including cancer. HCV medications either permanently remove (or clear) all remnants of the hepatitis C virus from the body or slow down liver damage and lower the risk of cirrhosis (advanced scarring of the liver).

Hepatitis C Treatment Market Summary and Scope

Hepatitis C Treatment Market Dynamics and Trends

Raising awareness about hepatitis C infection among people is expected to drive market growth.

HCV has been noted to kill more Americans than any other nationally notifiable infectious disease before COVID-19. HCV can be detected using readily available blood testing, and oral therapies lasting 8–12 weeks can cure nearly all infected patients with minor side effects. Unfortunately, most people infected with HCV are either unaware of their infection or are not receiving treatment. The World Health Organization (WHO) and U.S. National Academies of Sciences, Engineering, and Medicine have set HCV elimination strategies with the goals of reducing new HCV infections by 80% and HCV-related deaths by 65% by 2030. State and municipal governments, including those in San Diego County, have responded by launching their HCV-eradication programs. The San Diego County Board of Supervisors approved the Eliminate Hepatitis C San Diego County Initiative in January 2020, and the recommendations report was adopted on March 10, 2020. The initiative is a public-private partnership that aims to make recommendations and create a roadmap for achieving the WHO HCV elimination targets by improving screening strategies and connecting them to care and treatment, addressing and removing barriers to cure, reducing harm and preventing reinfection, and supporting policies that support HCV elimination. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

Stringent regulatory approvals of the products, high cost associated with hepatitis C treatment drugs are some of the factors the market is expected to get hampered in the forecast period. For instance, Harvoni (Ledipasvir & Sofosbuvir) medicine costs US$ 94,500 for a 12-week treatment or around US$ 1100 per pill.

Industry Analysis

COVID-19 Impact on Hepatitis C Treatment Market

The epidemic caused by the SARS-CoV-2 virus resulted in a global lockdown and wreaked havoc on the Hepatitis C treatment market. The pandemic has disrupted healthcare services, reducing opportunities to conduct routine hepatitis C virus antibody screening, clinical care, and treatment. For instance, HCV management centers saw a 50% reduction in new patients and follow-ups without a rigorous lockdown in Egypt. In February, March, and April of 2018, 2019, and 2020, a study done across three clinical locations in the United States, Japan, and Singapore found a significant decrease in the number of patients who visited liver clinics throughout the three clinical sites. Therefore, people living with undiagnosed hepatitis C virus during the pandemic may later become identified at more advanced stages of the disease, leading to higher morbidity and mortality rates.

Further, unidentified hepatitis C virus-infected individuals may continue to transmit the virus to others unknowingly. Thus, the COVID-19 pandemic has affected the market. However, the situation iS expected to improve gradually in the forecast period.

Hepatitis C Treatment Market Segmentation Analysis

Combination Therapy segment is expected to hold the largest market share in hepatitis C treatment market

The combination therapy segment is expected to dominate in 2020. In the United States, an estimated 4.1 million people are infected, and HCV is the principal cause of death from liver disease and the leading indication for liver transplantation. Recent studies have demonstrated that the use of a combination of antivirals, which target HCV without interferon (IFN), can cure HCV without additional toxicities. For instance, For genotypes 1, 4, 5, and 6, chronic hepatitis C (HCV) infection, the fixed-dose combination of ledipasvir-sofosbuvir is a successful and well-tolerated one-pill once-daily alternative. This direct-acting antiviral regimen was the first FDA-approved hepatitis C treatment without interferon or ribavirin. For cirrhotic and treatment-experienced patients, ledipasvir-sofosbuvir can be used without ribavirin in most genotype 1A patients.

Furthermore, individuals who have never received treatment, are not black, and do not have cirrhosis may be eligible for an 8-week treatment, which is as effective as 12 weeks in clinical trials and observational studies. It has been demonstrated to be safe and effective in patients with decompensated cirrhosis, just like sofosbuvir-velpatasvir, the second NS5B-NS5A inhibitor combo. Therefore, it has increased the demand for combination drugs, due to which the market segment is expected to hold the largest market share in the forecast period.

Hepatitis C Treatment Market Geographical Share

North America region holds the largest market share in the global hepatitis C treatment market

In 2020, North America accounted for the highest revenue share. The increasing prevalence of hepatitis C virus, rising transfusion-transmitted infections (TTIs), raising awareness about the people, increasing clinical trials by the key players and the highly structured health care industry are factors the market is expected to boost in the forecast period. For instance, according to the Centers for Disease Control and Prevention, In the United States, the estimated number of annual acute HCV infections grew considerably from 11,800 in 2010 to 57,500 in 2019, and the highest number of new HCV infections occurred among White persons. Still, the highest rate was among American Indian/Alaska Native persons. Moreover, from 2013 through 2019, the highest number and rates of new HCV infections have occurred in persons 20 through 39 years of age. Therefore, it has increased the demand for hepatitis C treatment in the North American region. Thus, it is expected to hold the largest market share in the forecast period.

Hepatitis C Treatment Companies and Competitive Landscape

Major key players in the hepatitis C treatment market are AbbVie Inc., Merck & Co., Inc., Gilead Sciences, Inc., Genentech, Inc., Kadmon Pharmaceuticals, LLC, Cipla Ltd, Mylan Laboratories Limited and Strides Arcolab Limited         .

Merck & Co., Inc.:

Overview:

Merck & Co., Inc. is a global health care company that delivers innovative health solutions through prescription medicines, vaccines, biologic therapies and animal health products. The company’s operations are principally managed on a product basis and include two operating segments: the pharmaceutical and animal health segments, both reportable. The pharmaceutical segment includes human health pharmaceutical and vaccine products. Moreover, the company is committed to being the premier, research-intensive biopharmaceutical company and is dedicated to providing leading innovations and solutions.

­Product Portfolio:

ZEPATIER (elbasvir and grazoprevir) tablets: ZEPATIER is a fixed-dose combination product containing elbasvir, a hepatitis C virus (HCV) NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor, and is indicated for the treatment of chronic HCV genotype 1 or 4 infections in adult and pediatric patients 12 years of age and older or weighing at least 30 kg. ZEPATIER is indicated for use with ribavirin in certain patient populations.